Selpercatinib for treating advanced thyroid cancer with RET alterations

2.1 Selpercatinib (Retsevmo, Eli Lilly) 'as monotherapy is indicated for the treatment of adults with advanced RET fusion-positive thyroid cancer who require systemic therapy following prior treatment with sorafenib and or lenvatinib'.

2.2 Selpercatinib 'as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC) who require systemic therapy following prior treatment with cabozantinib and or vandetanib'.

2.3 The dosage schedule is available in the summary of product characteristics.

2.4 The company-estimated cost of a 28‑day cycle of selpercatinib is £8,736.00. The company has a commercial arrangement. This makes selpercatinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.